Chemomab Therapeutics Ltd.
CMMBNASDAQHealthcare● Active
$1.81
+$0.04(+2.25%)
Market Cap$11139531
P/E Ratio—
52W High$5.48
52W Low$1.35
Chemomab Therapeutics Ltd. (CMMB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CMMB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.22
Est. -$0.04 · -450.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
CMMB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.04 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.04 | -$0.22 | -450.0% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.20 | -$0.24 | -20.0% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.20 | -$0.80 | -300.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.80 | -$0.36 | +55.0% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.20 | -$0.14 | +30.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.20 | -$0.16 | +20.0% | — | — | — |
| — Q4 FY2024 | Nov 14, 2024 | -$0.20 | -$0.20 | +0.0% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.22
EPS Est.
-$0.04
EPS Surpr.
-450.0%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.24
EPS Est.
-$0.20
EPS Surpr.
-20.0%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.80
EPS Est.
-$0.20
EPS Surpr.
-300.0%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.80
EPS Surpr.
+55.0%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.20
EPS Surpr.
+30.0%
Revenue
—
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.20
EPS Surpr.
+20.0%
Revenue
—
Q4 FY2024
Nov 14, 2024
EPS Actual
-$0.20
EPS Est.
-$0.20
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -450.0% | $1.74 | $1.70 | -2.30% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -20.0% | $2.00 | $1.93 | -3.50% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -300.0% | $2.68 | $2.55 | -4.85% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +55.0% | $3.83 | $3.59 | -6.27% |
| ▲ Q2 FY2025 | May 15, 2025 | +30.0% | $4.84 | $5.16 | +6.61% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +20.0% | $6.72 | $6.04 | -10.12% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +0.0% | $6.96 | $6.96 | +0.00% |
| ▼ Q3 FY2024 | Aug 21, 2024 | -30.0% | $4.96 | $4.88 | -1.61% |
Q2 FY2026-2.30%
Report Date
May 14, 2026
EPS Beat/Miss
-450.0%
Price Before
$1.74
Price After
$1.70
Q1 FY2026-3.50%
Report Date
Mar 19, 2026
EPS Beat/Miss
-20.0%
Price Before
$2.00
Price After
$1.93
Q4 FY2025-4.85%
Report Date
Nov 13, 2025
EPS Beat/Miss
-300.0%
Price Before
$2.68
Price After
$2.55
Q3 FY2025-6.27%
Report Date
Aug 14, 2025
EPS Beat/Miss
+55.0%
Price Before
$3.83
Price After
$3.59
Q2 FY2025+6.61%
Report Date
May 15, 2025
EPS Beat/Miss
+30.0%
Price Before
$4.84
Price After
$5.16
Q1 FY2025-10.12%
Report Date
Mar 3, 2025
EPS Beat/Miss
+20.0%
Price Before
$6.72
Price After
$6.04
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$6.96
Price After
$6.96
Q3 FY2024-1.61%
Report Date
Aug 21, 2024
EPS Beat/Miss
-30.0%
Price Before
$4.96
Price After
$4.88
Avg Beat Reaction-2.44%
Avg Miss Reaction-3.06%
Beat Rate4 / 8 quarters
Largest Move-10.12% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CMMB ends December
Chemomab Therapeutics Ltd. (CMMB) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.22 — missing the analyst consensus of $-0.04 by -450.0%. The next CMMB earnings date is expected around September 1, 2026.
Each quarter, investors track CMMB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CMMB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CMMB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CMMB earnings · 5 questionsChemomab Therapeutics Ltd.'s next earnings report is expected around September 1, 2026. CMMB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CMMB historically reports after market close (AMC).
CMMB earnings datewhen is CMMB earningsCMMB next earnings datewhen does CMMB report earningsCMMB earnings calendar
▸ Source: FMP · Chemomab Therapeutics Ltd. SEC filings · US GAAP · Chemomab Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026